Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 2, 1998, Pages 670-675

  Hoffmann, P ^a   Bernat, A ^a   Savi, P ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ASPIRIN; BENZYLAMINES; BLEEDING TIME; CAROTID ARTERY INJURIES; COLLAGEN; FIBRINOLYTIC AGENTS; HEMOSTASIS; JUGULAR VEINS; MALE; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RABBITS; THIAZOLES; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0032422449     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bernat A, Dol F, Herbert JM, Sainte-Marie M and Maffrand JP (1993) Potentiating effects of anticoagulants and antiplatelet agents on streptokinase-induced thrombolysis in the rabbit. Fibrinolysis 7: 23-30.
2. Born GV (1961) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927-929.
3. Caprie Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339.
4. Collen D, Stassen JM and Verstraete M (1983) Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 71: 368-376.
5. Collen D (1990) Thrombolytic therapy. Ann NY Acad Sci 112: 259-269.
6. Coller BS (1997) GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 78: 730-735.
7. Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP and Maffrand JP (1991) Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 65: 186-190.
8. Frederick LG, Suleymanov OD, King LW, Salyers AK, Nicholson NC and Feigen LP (1996) The protective dose of the potent GP IIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation 93: 129-134.
9. Harfenist EJ, Packham MA and Mustard JF (1988) Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits and rats. Blood 71: 132-136.
10. Harker LA (1997) The role of platelets in the early and late vascular responses initiated by mechanical vascular injury. Fibrinolysis & Proteolysis 11: suppl 1, 97-103.
11. Hennekens CH, Buring JE, Sandercock P, Collins R and Peto R (1989) Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 60: 749-756.
12. Hérault JP, Peyrou V, Savi P, Bernat A and Herbert JM (1998) Effect of SR 121566A, a potent GP Ilb-IIIa antagonist, on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 79: 383-388.
13. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger J, Necciari J, Defreyn G and Maffrand JP (1993) Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11: 180-198.
14. Herbert JM, Hérault JP, Bernat A, van Amsterdam RGM, Vogel GMT, Lormeau JC, Petitou M and Meuleman DG (1996) Biochemical and pharmacological properties of SANORG 32701. Comparison with the "Synthetic pentasaccharide" (SR90107/ ORG31540) and standard heparin. Circ Res 79: 590-600.
15. Hladovec I (1971) Experimental arterial thrombosis in rats with continuous registration. Thromb Diathes Haemorrh 26: 407-410.
16. Hoffmann P, Bernat A, Savi P and Herbert JM (1997) Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GPIIb/IIIa antagonist, in rabbits: Comparison with clopidogrel and aspirin. J Cardiovasc Pharmacol 30: 1-7.
17. Kawamura M, Imura Y, Moria N, Kita S, Fukushi H, Sugihara H, Nishikawa K and Terashita Z (1996) Antithrombotic effects of TAK-029, a novel GP IIb/IIIa antagonist, in guinea pigs: Comparative studies with ticlopidine, clopidogrel, aspirin and prostaglandin E1 and argatropan. J Pharmacol Exp Ther 277: 502-510.
18. Lind SE (1991) The bleeding time does not predict surgical bleeding. Blood 77: 2547-2552.
19. Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, De Grado WF, Thoolen MJ and Reilly TM (1994a) Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 89: 3-12.
20. Mousa SA, Forsythe MS, Diemer M, Bozarth JM and Reilly TM (1994b) Thrombolytic and antithrombotic efficacy of the platelet GPIIb/IIIa antagonist DMP728. Coronary Artery Disease 5: 919-927.
21. Nishiyama H, Umemura K, Wada K and Nakashima M (1995) Antithrombotic effect of a new glycoprotein IIb/IIIa antagonist, SC-52012A: Studies in two guinea-pig thrombosis models. Platelets 6: 283-287.
22. Panak E, Maffrand JP, Picard-Fraire C, Vallee E, Blanchard J and Roncucci R (1983) Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasia 13: suppl 1, 1-54.
23. Raddatz P and Gante J (1995) Recent developments in glycoprotein IIb/IIIa antagonists. Exp Opin Ther Patents 5: 1163-1183.
24. Savi P, Badorc A, Bordes MF, de Cointet P, Lale A, Bornia J, Poirier A, Maffrand JP, Bernat A, Hoffmann P and Herbert JM (1998) SR 121787: A potent, synthetic and orally active platelet fibrinogen receptor antagonist. Thromb Haemost in press.
25. Topol EJ (1997) Targeted approaches to thrombus inhibition - an end to the shotgun approach. Clin Cardiol 20: I-22-I-26.
26. Verhallen PFJ and Barth M (1991) Species comparison of anti-aggregatory properties of three fibrinogen receptor antagonists: RGDS, echistatin and the carboxy-terminal dodecapeptide of the fibrinogen gamma chain. Thromb Haemost 65: 1144.
27. Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM and Willerson JT (1994) Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 267 (Heart Circ Physiol 36): H488-H493.